| Trial ID: | L6281 |
| Source ID: | NCT06144788
|
| Associated Drug: |
Sglt2 Inhibitor
|
| Title: |
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: SGLT2 inhibitor
|
| Outcome Measures: |
Primary: Changes in HbA1c at the 12 week from the baseline, 12 week |
|
| Sponsor/Collaborators: |
Sponsor: Jeil Pharmaceutical Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
156
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2023-11
|
| Completion Date: |
2025-04
|
| Results First Posted: |
|
| Last Update Posted: |
2023-11-22
|
| Locations: |
Severance Hospital, Seoul, Seodaemun-gu, 03722, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT06144788
|
